U.S. Machinery Stock News

NYSE:FICO
NYSE:FICOSoftware

A Look At Fair Isaac’s Valuation As VantageScore Pressure Rises And US$1b Senior Notes Are Issued

Why Fair Isaac is back in focus Fair Isaac (FICO) has jumped back onto investors’ radar after two linked developments, rising pressure from rival credit scores in U.S. mortgages and a fresh US$1b senior notes issuance. Together, these moves have raised questions about how secure FICO’s core Scores business really is and how management is choosing to fund the next phase of the company’s evolution. See our latest analysis for Fair Isaac. FICO’s share price has been under pressure for several...
NasdaqGS:FLNC
NasdaqGS:FLNCElectrical

Fluence Energy (FLNC) Valuation Check As Bullish Solar And Storage Outlook Draws Investor Interest

Fluence Energy (FLNC) is back in focus after a bullish SEIA and Wood Mackenzie report pointed to strong U.S. solar and storage installations, with solar projected to lead new grid capacity additions in 2025. See our latest analysis for Fluence Energy. Fluence Energy’s recent moves reflect a mixed picture, with a 10.83% 7 day share price return and a 26.18% 90 day share price decline, yet a very large 1 year total shareholder return suggests longer term momentum has been stronger than the...
NYSE:DHR
NYSE:DHRLife Sciences

How Masimo Deal Risks And Governance Scrutiny At Danaher (DHR) Has Changed Its Investment Story

In recent days, Danaher has come under pressure after its US$9.90 billion Masimo acquisition raised questions about higher debt levels, integration risks, and a more cautious full-year 2026 outlook amid sector headwinds. At the same time, a law firm has begun investigating potential fiduciary duty breaches by certain officers and directors, while a Danaher subsidiary, IDBS, received an industry award for biopharma digitalisation in Asia-Pacific. These developments highlight how Danaher’s...
NasdaqGS:LSTR
NasdaqGS:LSTRTransportation

How Landstar’s Heavy Haul and Mexico Expansion Amid Softer Freight Demand Will Impact Landstar System (LSTR) Investors

In recent updates, Landstar System expanded its heavy haul and Mexico cross-border services while maintaining dividends, share repurchases, and a lower long-term debt load. This combination of operational expansion and financial conservatism contrasts with softer freight demand and capacity imbalances that have led analysts to trim earnings expectations. Now we’ll explore how analysts’ cautious earnings revisions, despite Landstar’s heavy haul and Mexico expansion, reshape the company’s...
NasdaqGS:ONC
NasdaqGS:ONCBiotechs

Is It Time To Reassess BeOne Medicines (ONC) After Recent Share Price Weakness

If you are wondering whether BeOne Medicines at around US$284.05 is giving you fair value or a potential mispricing, this article will walk through what the current market price might be saying about the business. The stock has seen mixed returns, with a 5.7% decline over the last 7 days and a 19.1% decline over the last 30 days, set against a 27.2% return over 3 years and 9.6% over 1 year. These figures can change how investors view both its growth prospects and risk. Recent coverage of...
NYSE:KAI
NYSE:KAIMachinery

Kadant (KAI) Valuation Check After Recent Share Price Pullback

Kadant stock moves: how recent returns stack up for long term holders Kadant (KAI) has seen mixed share performance recently, with a 5.5% decline over the past day and about 9.3% over the past month, while the past 3 months show a 3.9% gain. See our latest analysis for Kadant. Zooming out from the recent pullback, Kadant’s 1-day and 30-day share price returns of 5.5% and 9.3% declines contrast with a 6% year to date gain and a 56.2% three year total shareholder return. This suggests momentum...
NYSE:STC
NYSE:STCInsurance

Do Stewart Information Services' Dividend And Insider Buying Moves Reveal A Clearer Capital Allocation Playbook For STC?

Earlier this month, Stewart Information Services’ board declared a first-quarter 2026 cash dividend of US$0.525 per share, while director Bradley C. Allen Jr. purchased 1,000 shares on March 10, 2026, adding to his accumulated insider buying over the past year. Together, the sustained dividend and director share purchase highlight active insider participation and a board signaling confidence in the company’s cash generation and operations. Next, we’ll examine how the reaffirmed dividend...
NYSE:AORT
NYSE:AORTMedical Equipment

How Investors May Respond To Artivion (AORT) Analyst Optimism Around NEXUS Stent Graft Trial Results

In recent days, analysts at Canaccord Genuity and Stifel reiterated positive views on Artivion, highlighting the aortic disease pipeline and particularly the NEXUS stent graft system after one-year trial data showed strong sealing and low endoleak rates, with physicians indicating plans to adopt the device if it receives FDA approval. This combination of supportive clinical evidence and physician interest underscores how Artivion’s pipeline products could strengthen its position in treating...
NasdaqGS:ENVX
NasdaqGS:ENVXElectrical

Enovix (ENVX) Valuation Revisited As Laser Dicing Setbacks Temper Analyst Expectations

Why laser dicing issues put Enovix (ENVX) in the spotlight Enovix (ENVX) has been drawing attention after several analysts flagged laser dicing problems that are affecting production yields, slowing battery qualification for a key customer and prompting reduced expectations despite continued positive ratings. See our latest analysis for Enovix. Those manufacturing concerns have been reflected in Enovix’s share price, with a 30 day share price return showing a 19.41% decline and a 90 day share...
NYSE:AA
NYSE:AAMetals and Mining

Alcoa (AA) Valuation Check As Data Center Land Sales And Analyst Shifts Draw Attention

Alcoa (AA) has moved to sell ten closed industrial sites to data center firms, repurposing idle smelter real estate that sits close to power sources and linking its traditional aluminum business to computing demand. See our latest analysis for Alcoa. Alcoa's stock has seen a sharp shift in sentiment over recent months, with a 37.82% 90 day share price return and a 91.78% 1 year total shareholder return, even after a 3.55% one day pullback to US$63.59, as investors weigh data center land...
NasdaqGM:TNGX
NasdaqGM:TNGXBiotechs

Assessing Tango Therapeutics (TNGX) Valuation After Vopimetostat Progress And New Erasca Collaboration

Tango Therapeutics (TNGX) is back in focus after reporting fourth quarter and full year 2025 results, outlining a funding runway beyond 2028, and signing a new clinical trial collaboration with Erasca for difficult cancers. See our latest analysis for Tango Therapeutics. The earnings update, extended funding runway and new Erasca collaboration appear to have coincided with building momentum, with the 30 day share price return of 37.19% and year to date share price return of 93.73% sitting...
NYSE:ELF
NYSE:ELFPersonal Products

Is It Time To Reassess e.l.f. Beauty (ELF) After Its Multi Year Share Price Surge

If you are wondering whether e.l.f. Beauty's share price still reflects its true worth after a strong multi year run, looking closely at its valuation can help put the current price into context. The stock last closed at US$73.41, with returns of an 11% decline over the past 7 days, a 4.4% decline over 30 days, a 5.7% decline year to date, a 7.7% gain over 1 year, 1.3% over 3 years, and a very large gain over 5 years. Recent price moves sit against a backdrop of ongoing interest in e.l.f...
NYSE:CHE
NYSE:CHEHealthcare

Is It Time To Reassess Chemed (CHE) After A 32% One Year Share Price Slide

If you are wondering whether Chemed is attractively priced after a tough stretch, this article walks through what the current share price may be implying about its value. The stock closed at US$401.87, with returns of a 1.5% decline over 7 days, 13.2% decline over 30 days, 5.2% decline year to date, 32.5% decline over 1 year, 21.0% decline over 3 years and 9.6% decline over 5 years. This performance may change how investors think about its risk and return trade off. Recent coverage around...
NYSE:MGY
NYSE:MGYOil and Gas

Did Magnolia’s Reserve Gains and 52-Week High Just Shift Magnolia Oil & Gas’ (MGY) Investment Narrative?

In recent days, Magnolia Oil & Gas reported an 11% increase in proved developed producing reserves, fourth-quarter net income of US$71.4 million, and year-on-year production growth to 103,800 barrels of oil equivalent per day. At the same time, insider share sales and a new 52-week high coincided with analysts highlighting Magnolia’s stronger reserve base and operational efficiency amid shifting geopolitical conditions for oil markets. We’ll now examine how Magnolia’s improved reserves and...
NYSE:LAZ
NYSE:LAZCapital Markets

Assessing Lazard (LAZ) Valuation After Sector-Wide Selloff On Geopolitics And Liquidity Concerns

Lazard (LAZ) has been caught in a sector wide selloff, as geopolitical tensions, higher crude prices, and JPMorgan’s lending pullback to private credit providers have fueled liquidity worries and pressured financial stocks. See our latest analysis for Lazard. At a share price of US$40.53, Lazard has seen a 1 day share price return of 0.37% decline, a 7 day share price return of 9.21% decline, and a 30 day share price return of 26.03% decline. Its 1 year total shareholder return of 5.99%...
NasdaqGS:WBD
NasdaqGS:WBDEntertainment

Assessing Warner Bros. Discovery (WBD) Valuation After Mixed Returns And A Cancelled Netflix Deal

Why Warner Bros. Discovery Stock Is on Investors’ Radar Warner Bros. Discovery (WBD) continues to attract attention as investors weigh its recent share performance, with the stock showing a 1 day return of 1.06% and a past 3 months return of 9.47%. Those moves sit alongside a reported US$37.3b in revenue and US$728m in net income. This has prompted many to reassess how the media group’s Streaming, Studios, and Global Linear Networks segments stack up at the current US$27.14 share price. See...
NasdaqGS:BMBL
NasdaqGS:BMBLInteractive Media and Services

Bumble (BMBL) Is Up 23.2% After AI-Led Bumble 2.0 Reveal And Upbeat 2026 Revenue Guidance

In March 2026, Bumble reported fourth-quarter 2025 results that exceeded revenue and earnings expectations, issued first-quarter 2026 revenue guidance of US$209 million to US$213 million (including US$171 million to US$174 million from the Bumble app), and highlighted stronger profitability despite fewer paying users. The company also unveiled an AI-powered overhaul, including its Bee model, the Dates assistant and the upcoming Bumble 2.0 cloud-native platform, aiming to improve user...
NYSE:PRGO
NYSE:PRGOPharmaceuticals

A Look At Perrigo’s (PRGO) Valuation As UBS Conference Appearance Draws New Attention

Why Perrigo’s UBS conference appearance is drawing fresh attention Perrigo (PRGO) is set to present at the UBS Global Consumer and Retail Conference in New York on March 11, 2026, with President and CEO Patrick Lockwood-Taylor scheduled to speak. The event has put a fresh spotlight on the stock, as investors look for updated commentary on Perrigo’s over the counter health and wellness portfolio, recent financial results, and how management is thinking about capital allocation. See our latest...
NYSE:APTV
NYSE:APTVAuto Components

Versigent Spin-Off And Debt Tender Could Be A Game Changer For Aptiv (APTV)

Aptiv’s board has approved the spin-off of its Electrical Distribution Systems business into a new, independent public company called Versigent, and its subsidiary Aptiv Swiss Holdings has launched a cash tender offer of up to US$1.35 billion for outstanding notes, contingent on completing the separation and receiving at least US$1.70 billion in special dividends from Versigent. By pairing the Versigent spin-off with new bond issuances and a sizable tender offer, Aptiv is actively reshaping...
NYSE:ELV
NYSE:ELVHealthcare

Does Medicare Sanction Threat Versus Growth Push Change The Bull Case For Elevance Health (ELV)?

In early March 2026, a federal Medicare regulator warned Elevance Health that it may face intermediate sanctions over alleged noncompliance with risk‑adjustment and data submission rules, potentially halting new enrollments for certain Medicare Advantage prescription drug plans if issues are not resolved. At the same time, Elevance Health reaffirmed its 2026 earnings and benefit expense guidance and expanded clinical partnerships such as Myomo’s orthotic device coverage, highlighting a...
NasdaqGS:PLTR
NasdaqGS:PLTRSoftware

Is Palantir’s New Wave of NVIDIA‑Backed Defense and Industrial AI Deals Altering The Investment Case For Palantir Technologies (PLTR)?

In March 2026, Palantir Technologies and partners including Ondas, World View, GE Aerospace, Centrus Energy, LG CNS, NVIDIA, and Polymarket announced a wave of collaborations applying Palantir’s AI platforms to defense, aerospace, industrial operations, sovereign AI data centers, and sports integrity monitoring. These agreements highlight Palantir’s push to embed its Artificial Intelligence Platform and related software as core infrastructure across high-stakes sectors, from military...
NYSE:HUM
NYSE:HUMHealthcare

Is It Time To Reconsider Humana (HUM) After Its Steep Share Price Slide?

If you are looking at Humana and wondering whether the recent share price puts it in bargain territory or not, it helps to start with the facts behind the current valuation story. Humana's share price most recently closed at US$165.43, with returns of a 7.7% decline over 7 days, a 5.7% decline over 30 days, a 37.5% decline year to date, a 33.7% decline over 1 year, a 65.5% decline over 3 years, and a 57.7% decline over 5 years. Recent headlines around Humana have focused on how the share...
NasdaqGS:MMSI
NasdaqGS:MMSIMedical Equipment

Will Wells Fargo’s Downgrade and Selling Wave Change Merit Medical Systems’ (MMSI) Narrative

In recent weeks, Merit Medical Systems faced a shift in Wall Street opinion when Wells Fargo downgraded its rating, prompting a period of sustained institutional selling despite no major operational changes. What stands out is that the company’s underlying operations and financial health remain solid, suggesting investor sentiment has moved more than the business fundamentals. We’ll now explore how Wells Fargo’s downgrade and the resulting sentiment shift may influence Merit Medical...
NYSE:MTN
NYSE:MTNHospitality

A Look At Vail Resorts (MTN) Valuation After Weak Snowfall And 2026 Guidance Cut

Weather hit, guidance cut: why Vail Resorts stock is back in focus Vail Resorts (MTN) is under the spotlight after one of the weakest snowfall seasons in over 30 years led to fewer skier visits, softer revenue across business lines, and a cut to 2026 earnings guidance. See our latest analysis for Vail Resorts. Those weather headwinds and the cut to 2026 guidance have weighed on sentiment, with a 90 day share price return of 18.56% and a 1 year total shareholder return of 12.46% in decline...